Noboru Kubodera

Noboru Kubodera

Auto-generated profile, based on publicly available information

Noboru Kubodera

Disease Area Strategy Dept. 2. Chugai Pharmaceutical Co., Ltd. 2-1-1 Nihonbashi-Muromachi, Chuo-ku, Tokyo 103-8324, Japan

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2003 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
NKN. Kubodera
N. Kubodera
NTN. Tsuji
N. Tsuji
YUY. Uchiyama
Y. Uchiyama
KEK. Endo
K. Endo

29 September 2009 in Molecules
Verified
Journal Article
Open access
PDF file
NKNoboru Kubodera
Noboru Kubodera
Alfacalcidol (1α-hydroxyvitamin D3) has been widely used since 1981 as a prodrug for calcitriol (1α,25-dihydroxyvitamin D3) in the treatment of hypocalcemia, chronic renal failure, hypoparathyroidism and osteoporosis. More recently, doxercalciferol (1α-hydroxyvitamin D2) has been used since 1999 as a prodrug for 1α,25-dihydroxyvitamin D2 for the treatment of secondary hyperparathyroidism. Currently, six forms of vitamin D are known. They range from vitamin D2 to vitamin D7 and are distinguished by their differing side chains. Only vitamin D2 and vitamin D3 have been found to be biologically active based on the elucidation of activation pathways. Alfacalcidol and osteoporosis/doxercalciferol and secondary hyperparathyroidism are discussed, with a new look at old compounds including their practical syntheses.

31 December 1998 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YOYoshiyuki Ono
Yoshiyuki Ono
AKAkira Kawase
Akira Kawase
HWHiroyoshi Watanabe
Hiroyoshi Watanabe
ASAyako Shiraishi
Ayako Shiraishi
STSatoshi Takeda
Satoshi Takeda
NKNoboru Kubodera
Noboru Kubodera

1 October 2009 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
NKNoboru Kubodera
Noboru Kubodera
Many readers may have only a vague idea about vitamin D. This is made complicated, in part, because it is also expressed with suffixes such as vitamin D2 or vitamin D3. Otherwise the prefix of “active” is also occasionally used. Vitamin D is often referred to as an important nutrient for calcium intake, especially for growing children and the elderly. On the other hand, it serves as a therapeutic drug for osteoporosis and psoriasis. Recent studies have suggested an association with a number of diseases such as cancer, diabetes and Alzheimers disease. The author has been involved in the research and development of vitamin D applications for over 25 years, and has often witnessed even world-class experts confuse the two roles - vitamin and hormone - of “substance” D. Assuming some readers are not familiar with vitamin D, D hormone or osteoporosis, an outline of vitamin D and D hormone is delineated with a particular focus on the treatment of osteoporosis. Furthermore, development of alfacalcidol as the first prodrug of D hormone (calcitriol) and eldecalcitol as a characteristic new D hormone derivative and basic relationship between calcemic activity and effect on bone in vitamin D (cholecalciferol), D hormone (calcitriol/alfacalcidol), and a new D hormone derivative (eldecalcitol) are introduced.

1 July 1997 in Synthetic Communications
Verified
Journal Article
Closed access
TMTetsuhiro Mikami
Tetsuhiro Mikami
TITomoyasu Iwaoka
Tomoyasu Iwaoka
MKMasahiro Kato
Masahiro Kato
HWHiroyoshi Watanabe
Hiroyoshi Watanabe
NKNoboru Kubodera
Noboru Kubodera
A practically useful formation of γ-keto or γ-hydroxy ether linkage from alcohol, for the construction of the side chain of 1α, 25-dihydroxy-22-oxavitamin D3 (OCT), is described.

1 January 2001 in Chirality
Verified
Journal Article
Closed access
PDF file
KMKoichi Mikami
Koichi Mikami
SOShiho Ohba
Shiho Ohba
HOHirofumi Ohmura
Hirofumi Ohmura
NKNoboru Kubodera
Noboru Kubodera
KNKimie Nakagawa
Kimie Nakagawa
TOToshio Okano
Toshio Okano